XTX Topco Ltd Acquires 52,498 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

XTX Topco Ltd grew its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 99.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,056 shares of the company’s stock after acquiring an additional 52,498 shares during the period. XTX Topco Ltd owned about 0.13% of Editas Medicine worth $133,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of EDIT. Renaissance Technologies LLC bought a new stake in shares of Editas Medicine during the 4th quarter valued at $1,843,000. Monaco Asset Management SAM bought a new stake in shares of Editas Medicine during the 4th quarter valued at $1,359,000. Raymond James Financial Inc. bought a new stake in shares of Editas Medicine during the 4th quarter valued at $303,000. Aristides Capital LLC bought a new stake in shares of Editas Medicine during the 4th quarter valued at $168,000. Finally, Sei Investments Co. bought a new stake in shares of Editas Medicine during the 4th quarter valued at $106,000. Institutional investors own 71.90% of the company’s stock.

Editas Medicine Stock Down 1.9 %

Editas Medicine stock opened at $1.55 on Wednesday. The company’s 50-day moving average price is $1.43 and its 200-day moving average price is $1.81. Editas Medicine, Inc. has a twelve month low of $0.91 and a twelve month high of $6.69. The company has a market cap of $129.75 million, a PE ratio of -0.61 and a beta of 2.16.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The business had revenue of $30.60 million during the quarter, compared to the consensus estimate of $37.17 million. During the same quarter last year, the firm earned ($0.23) earnings per share. As a group, sell-side analysts expect that Editas Medicine, Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright began coverage on shares of Editas Medicine in a research report on Monday. They set a “buy” rating and a $3.00 price objective for the company. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Editas Medicine has a consensus rating of “Hold” and a consensus target price of $6.54.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.